You are here
beloranib leads to significant weight loss
Final efficacy and safety data from a completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2 (MetAP2), demonstrated significant weight loss and improvements in cardiometabolic risk markers in 147 obese individuals over 12 weeks of treatment. The research was presented at the 30th Annual Meeting for the American Society for Metabolic and Bariatric Surgery (ASMBS) during ObesityWeek 2013, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity. The event was hosted by the ASMBS and The Obesity Society (TOS).
"These full Phase 2 results are an exciting prospect for the treatment of severely obese patients," said Dr Louis Aronne, Clinical Professor of Medicine at Weill Cornell Medical College. "Beloranib continues to demonstrate a unique ability to deliver rapid and significant weight loss as well as meaningful improvements in key cardiometabolic risk markers. Based on this supporting data, beloranib has the potential to be a highly effective and promising treatment option for life-threatening, severe obesity."
Beloranib, a novel obesity therapy that utilises a unique mechanism of action, is being studied for its ability to reduce body weight and improve cardiometabolic risk factors in obese patients. It is the first compound in its class that works by targeting MetAP2, which controls the production and utilisation of fatty acids. Inhibitors of MetAP2 reduce hunger while also reducing the production of new fatty acid molecules by the liver and helping to convert stored fats into useful energy.
The study presented was a randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a dose range of beloranib administered as twice-weekly subcutaneous injections for 12 weeks.
The trial enrolled 147 patients, of which 122 completed the study. Subjects were mostly obese women with mean age 48.4 years, body weight 100.9 kg, and BMI 37.6, who were enrolled into one of the four arms of the trial (n=37 in 0.6mg, 37 in 1.2mg, 35 in 2.4mg and 38 in placebo arm). Patients were allowed to eat normally and were not counselled to change their diet or exercise habits.
Results from this study showed that after 12 weeks of treatment, subjects on 0.6mg, 1.2mg, or 2.4mg of beloranib lost on average (+/- standard error of mean) -5.5 +/- 0.5kg, -6.9 +/- 0.6kg, and -10.9 +/- 1.1kg, respectively vs. -0.4 +/- 0.4 kg for those on placebo (all p<0.0001 vs. placebo).
The study also showed that weight loss with beloranib was progressive and continuing at week 12, reduced sense of hunger, improved cardiometabolic risk markers, and was generally well-tolerated. In addition to confirming the findings from previous studies that showed improvements in LDL-cholesterol, HDL-cholesterol and triglycerides, this study also demonstrated beloranib's effects to lower blood pressure.
Using 24-hour Ambulatory Blood Pressure Monitoring, clinically and statistically significant improvements in systolic blood pressure were observed for the 1.2mg and 2.4mg doses, showing reductions of 7.6mmHg and 12.0 mmHg, respectively.
There were no serious adverse events deemed to be related to the study drug and no clinically significant abnormal laboratory measures, vital signs, or electrocardiography findings. The most common adverse events with a higher incidence rate in those taking beloranib vs. placebo were nausea, diarrhoea, headache, injection site bruising, and insomnia. These adverse events were generally mild, transient and self-limiting in nature.
"The latest results from this robust, larger scale trial represent the first full set of Phase 2 data for beloranib in severely obese patients," said Dr Thomas Hughes, President and CEO of Zafgen. "This patient population often remains beyond the reach of existing pharmacotherapy and there is a major unmet medical need for treatment of this serious disease. We are very encouraged by the extent of weight loss observed in this trial and will continue to pursue beloranib as a pharmacological alternative to bariatric surgery."
Beloranib is being developed as a twice-weekly subcutaneous injection for severe obesity. Zafgen holds exclusive worldwide rights (exclusive of Korea) for development and commercialisation of beloranib.